A new FDA-approved test offered by Mayo Clinic Laboratories is expanding testing options for patients with Alzheimer’s disease. The new test, AMYR, assesses amyloid pathology in Alzheimer's disease (AD) and measures protein markers in cerebrospinal fluid. It is currently approved for patients age 55 and older who present with cognitive impairment and are being assessed for Alzheimer’s disease (AD) and other causes of cognitive decline.

Mayo Clinic Laboratories continues to offer its existing AD evaluation (Mayo ID: ADEVL) in addition to the new AMYR test.

For more information, listen to this “Test in Focus” podcast episode on Mayo Clinic Laboratories Insights.